Table 2.
Summary of ongoing clinical trials using MSCs for ischemic heart disease
| Study | n | Cell source | Condition | Design | Delivery | ClinicalTrials ID |
|---|---|---|---|---|---|---|
| Acute myocardial infarction | ||||||
| RELIEF | 135 | Autologous BM | Acute MI | Phase III | IC | NCT01652209 |
| CIRCULATE | 105 | Allogeneic BM | Acute MI | Phase II/III | IC | NCT03404063 |
| HUC‐HEART | 79 | Autologous/allogeneic BM | Pre‐CABG | Phase I/II | IM | NCT02323477 |
| Kumar et al. | 20 | Allogeneic BM | Acute MI | Phase I/II | IV | NCT00883727 |
| Perin et al. | 25 | Allogeneic BM | Acute MI | Phase I/II | IM | NCT00555828 |
| Skerrett et al. | 220 | Allogeneic BM (PROCHYMAL) | Acute MI | Phase II | IV | NCT00877903 |
| Musialek et al. | 115 | Allogeneic BM (Cardiocell) | Acute MI | Phase II/III | IC | NCT03404063 |
| AMICI | 105 | Allogeneic BM | Acute MI | Phase II | IC | NCT01781390 |
| ESTIMATION | 50 | Autologous BM | Postacute MI | Phase III | IM | NCT01394432 |
| Chronic ischemic heart disease | ||||||
| Jerome et al. | NYD | Autologous BM | Ischemic CM (LVAD) | Phase I | IM | NCT02460770 |
| MESAMI2 | 90 | Autologous BM | Chronic ischemic CM | Phase II | IM | NCT02462330 |
| Dai et al. | 45 | Autologous BM | Chronic ischemic CM | Phase I/II | Collagen scaffold | NCT02635464 |
| CONCERT‐HF | 144 | Autologous BM | Ischemic CM | Phase II | IM | NCT02501811 |
| Antonitsis et al. | 30 | Allogeneic BM | Ischemic CM needing CABG | Phase I | IM | NCT01753440 |
| Antonitisis et al. | 5 | Allogeneic BM | Ischemic CM with LVAD | Phase I | IM | NCT01759212 |
| Kastrup et al. | 10 | Allogeneic adipose tissue | Ischemic CM | Phase I | IM | NCT02387723 |
| Kastrup et al. | 81 | Allogeneic adipose tissue | Ischemic CM | Phase II | IM | NCT03092284 |
| SCIENCE | 138 | Allogeneic adipose tissue | Ischemic CM | Phase II | IM | NCT02673164 |
| UCMSC‐Heart | 40 | Allogeneic UC | Ischemic CM | Phase I/II | IC | NCT02439541 |
| TRIDENT | 40 | Allogeneic BM | Ischemic CM | Phase II | IM | NCT02013674 |
| DREAM HF‐1 | 600 | Allogeneic BM (rexlemestrocel‐L) | Ischemic CM | Phase III | IM | NCT02032004 |
| SEESUPIHD | 64 | Allogeneic UC | Ischemic CM | Phase I/II | IC | NCT02666391 |
| TPAABPIHD | 200 | Autologous BM | Ischemic CM | Phase I/II | NYD | NCT02504437 |
| Maskon et al. | 80 | Autologous BM | Ischemic dilated CM | Phase II | IC | NCT01720888 |
| Harjula et al. | 60 | Autologous BM | Ischemic CM needing CABG | Phase II | IM | NCT00418418 |
| TAC‐HFT‐II | 55 | Autologous BM ± CSC | Ischemic CM | Phase I/II | IM | NCT02503280 |
| TEAM‐AMI | 124 | Autologous BM | Ischemic CM | Phase II | IC | NCT03047772 |
| Nonischemic cardiomyopathy | ||||||
| Hu et al. | 30 | Umbilical cord | Idiopathic dilated CM | Phase I | IM | NCT01219452 |
| Olson et al. | 45 | Allogeneic BM | Anthracycline‐mediated CM | Phase I | IV | NCT02408432 |
| Fernandez‐Avilez et al. | 70 | Autologous BM | Idiopathic dilated CM | Phase I/II | IM | NCT01957826 |
| Bartolucci et al. | 30 | Allogeneic UC | Dilated CM | Phase I/II | IV | NCT01739777 |
Abbreviations: BM, bone marrow; CABG, coronary artery bypass grafting; CM, cardiomyopathy; CSC, cardiac stem cells; IC, intracoronary; IM, intramyocardial; IV, intravenous; LVAD, left ventricular assist device; MI, myocardial infarction; MSC, mesenchymal stem cell; NYD, not yet determined; UC, umbilical cord.